Civic Intelligence

Rare Trait Hope Fund

990EZ • Fiscal year 2024 • EIN 46-2762646

Jan 01, 2024 to Dec 31, 2024 • Filed on Nov 17, 2025

Organization Profileraretrait.org
406 Schlief DriveBelle Chasse, LA 70037

(504) 408-1126

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

87th percentile

0.36x

Higher debt load relative to assets than 87% of similar nonprofits.

2024 filings • 501(c)3 • <$500k nonprofits • Source year 2024

Liabilities / Revenue

87th percentile

0.19x

Higher debt load relative to revenue than 87% of similar nonprofits.

2024 filings • 501(c)3 • <$500k nonprofits • Source year 2024

Net Margin

61st percentile

9.8%

Higher net margin than 61% of similar nonprofits.

2024 filings • 501(c)3 • <$500k nonprofits • Source year 2024

Top Officer Pay

79th percentile

$0

Higher top officer pay than 79% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2024 filings • 501(c)3 • <$500k nonprofits • Source year 2024

Asset Growth

93rd percentile

116%

Faster asset growth than 93% of similar nonprofits.

2024 filings • 501(c)3 • <$500k nonprofits • Annualized from 2023 to 2024

Revenue Growth

80th percentile

41%

Faster revenue growth than 80% of similar nonprofits.

2024 filings • 501(c)3 • <$500k nonprofits • Annualized from 2023 to 2024

Balance Sheet
Liabilities / Assets87th percentile

Assets

Up

$55,991

Up $30,124 (+116%) from 2023

Net Assets

Up

$35,991

Up $10,124 (+39%) from 2023

Liabilities

Up

$20,000

Up $20,000 from 2023

Revenue And Expenses
Liabilities / Revenue87th percentileNet Margin61st percentile

Revenue

Up

$103,771

Up $29,966 (+41%) from 2023

Expenses

Down

$93,647

Down $128,536 (-58%) from 2023

Net Income

Up

$10,124

Up $158,502 (+107%) from 2023

Historical Trend

Balance Sheet Trend

Asset Growth93rd percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$600K$400K$200K$0Assets 2014: $90,615Liabilities 2014: $02014Assets 2015: $110,975Liabilities 2015: $02015Assets 2016: $58,002Liabilities 2016: $02016Assets 2017: $124,476Liabilities 2017: $02017Assets 2018: $101,211Liabilities 2018: $02018Assets 2019: $125,131Liabilities 2019: $02019Assets 2020: $203,255Liabilities 2020: $0Net Assets 2020: $203,2552020Assets 2021: $540,668Liabilities 2021: $0Net Assets 2021: $540,6682021Assets 2022: $174,245Liabilities 2022: $0Net Assets 2022: $174,2452022Assets 2023: $25,867Liabilities 2023: $0Net Assets 2023: $25,8672023Assets 2024: $55,991Liabilities 2024: $20,000Net Assets 2024: $35,9912024

Highlighted filing

2024

Assets$55,991
Liabilities$20,000
Net Assets$35,991
Open 2024 Filing

Operations Trend

Revenue Growth80th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$1.0M$500K$0-$500KRevenue 2014: $143,671Expenses 2014: $53,055Net Income 2014: $90,6162014Revenue 2015: $104,197Expenses 2015: $76,229Net Income 2015: $27,9682015Revenue 2016: $68,404Expenses 2016: $121,377Net Income 2016: -$52,9732016Revenue 2017: $69,600Expenses 2017: $3,125Net Income 2017: $66,4752017Revenue 2018: $55,481Expenses 2018: $78,747Net Income 2018: -$23,2662018Revenue 2019: $32,324Expenses 2019: $8,403Net Income 2019: $23,9212019Revenue 2020: $78,386Expenses 2020: $262Net Income 2020: $78,1242020Revenue 2021: $410,842Expenses 2021: $73,429Net Income 2021: $337,4132021Revenue 2022: $260,648Expenses 2022: $627,071Net Income 2022: -$366,4232022Revenue 2023: $73,805Expenses 2023: $222,183Net Income 2023: -$148,3782023Revenue 2024: $103,771Expenses 2024: $93,647Net Income 2024: $10,1242024

Highlighted filing

2024

Revenue$103,771
Expenses$93,647
Net Income$10,124
Open 2024 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
Nov 17, 2025
Return Version
2024v5.0
Gross Receipts
$103,771
Mission and Program Overview

Mission

The mission and primary exepmt purpose is to facilitate research, raise funds and support development of treatments for Aspartylglucosaminuria (AGU); to be the resource for doctors, scientists and families world-wide; to increase awareness of rare diseases in general and Aspartylglucosaminuria in particular.

Program Services

DescriptionGrantsExpenses
AGA drug product vector safety and toxicology study per task order 1, agreement #AGR00026049 signed October 17, 2022$0$52,000
Per FDA feedback from pre-IND meeting in 2018, gene therapy product production is complete. It will be used in a clinical trial for AGU treatment.$0$38,643
Setting up AGU patient registry$0$300
Compensation and Service Providers
Top Officer Pay79th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
Julia TaravellaPresident, Executive DirectorFT$0--
Alla ComardelleMedical DirectorPT$0--
Emily MoranDirectorPT$0--
Guzel BilyalovaSecretary, TreasurePT$0--
Erik HeywoodDirector-$0--
Jody TaravellaDirectorPT$0--
Filing and Contact Details

Filer

Filer Name
Rare Trait Hope Fund
EIN
46-2762646
Phone
5044081126
Address
406 Schlief Drive, Belle Chasse, LA 70037

Signing Officer

Name
Julia Taravella
Title
Director
Phone
5043883732
Signed
2025-11-17
Supplemental Narrative

Additional Explanations

Form 990-EZ, Part I, Line 16

“Description;Amount^Charles River Laboratories Inc Wilmington MA 01887;51083|UTSW Viral Vector Core Dallas TX;37560|Greenwood Genetics Center;2000|National Organization for Rare Diseases;300|Travel Expences;1422|Bank Fees;563|Software and IT;177^Total;93105^”

Form 990-EZ, Part II, Line 26

“Description;EOY Amount^Personal loan from J Taravella;20000^Total;20000^”

Raw XML Appendix181 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd00
IRS990EZ/BenefitsPaidToOrForMembersAmt00
IRS990EZ/BooksInCareOfDetail/PersonNm0Julia Taravella
IRS990EZ/BooksInCareOfDetail/PhoneNum05043883732
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0406 Schlief Drive
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0Belle Chasse
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0LA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd070037
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt025867
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt055991
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd00
IRS990EZ/ContributionsGiftsGrantsEtcAmt0103771
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DirectIndirectPltclExpendAmt00
IRS990EZ/DonorAdvisedFndsInd00
IRS990EZ/EngagedInExcessBenefitTransInd00
IRS990EZ/ExcessOrDeficitForYearAmt010124
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt0360
IRS990EZ/FiledScheduleAInd01
IRS990EZ/ForeignFinancialAccountInd00
IRS990EZ/ForeignOfficeInd00
IRS990EZ/Form1120PolFiledInd00
IRS990EZ/Form990TotalAssetsGrp/BOYAmt025867
IRS990EZ/Form990TotalAssetsGrp/EOYAmt055991
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GainOrLossFromSaleOfAssetsAmt00
IRS990EZ/GamingGrossIncomeAmt00
IRS990EZ/GrantsAndSimilarAmountsPaidAmt00
IRS990EZ/GrossProfitLossSlsOfInvntryAmt00
IRS990EZ/GrossReceiptsAmt0103771
IRS990EZ/GrossSalesOfInventoryAmt00
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt00
IRS990EZ/LandAndBuildingsGrp/BOYAmt00
IRS990EZ/LandAndBuildingsGrp/EOYAmt00
IRS990EZ/LobbyingActivitiesInd00
IRS990EZ/MadeLoansToFromOfficersInd00
IRS990EZ/MembershipDuesAmt00
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt025867
IRS990EZ/NetAssetsOrFundBalancesEOYAmt035991
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt025867
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt035991
IRS990EZ/OccupancyRentUtltsAndMaintAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt040
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt120.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt25
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt35
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt42
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt55
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0Julia Taravella
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1Alla Comardelle
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2Emily Moran
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3Guzel Bilyalova
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4Erik Heywood
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5Jody Taravella
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0President, Executive Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Medical Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Secretary, Treasure
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Director
IRS990EZ/OperateHospitalInd00
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd00
IRS990EZ/OrganizationHadUBIInd00
IRS990EZ/OtherAssetsTotalDetail/BOYAmt00
IRS990EZ/OtherAssetsTotalDetail/EOYAmt00
IRS990EZ/OtherChangesInNetAssetsAmt00
IRS990EZ/OtherExpensesTotalAmt093105
IRS990EZ/OtherRevenueTotalAmt00
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd00
IRS990EZ/PrimaryExemptPurposeTxt0The mission and primary exepmt purpose is to facilitate research, raise funds and support development of treatments for Aspartylglucosaminuria (AGU); to be the resource for doctors, scientists and families world-wide; to increase awareness of rare diseases in general and Aspartylglucosaminuria in particular.
IRS990EZ/PrintingPublicationsPostageAmt0182
IRS990EZ/ProgramServiceRevenueAmt00
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0Per FDA feedback from pre-IND meeting in 2018, gene therapy product production is complete. It will be used in a clinical trial for AGU treatment.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt1AGA drug product vector safety and toxicology study per task order 1, agreement #AGR00026049 signed October 17, 2022
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt2Setting up AGU patient registry
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt00
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt10
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt20
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt038643
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt152000
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt2300
IRS990EZ/ProhibitedTaxShelterTransInd00
IRS990EZ/RelatedOrganizationCtrlEntInd00
IRS990EZ/SalariesOtherCompEmplBnftAmt00
IRS990EZ/SaleOfAssetsGrossAmt00
IRS990EZ/SchoolOperatingInd00
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/SpecialEventsNetIncomeLossAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0LA
IRS990EZ/SubjectToProxyTaxInd00
IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt00
IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt020000
IRS990EZ/TanningServicesProvidedInd00
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt093647
IRS990EZ/TotalProgramServiceExpensesAmt090943
IRS990EZ/TotalRevenueAmt0103771
IRS990EZ/TransactionWithControlEntInd00
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd00
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0raretrait.org
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt0123771
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt073805
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0260648
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt0410842
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt078386
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0947452
IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct01
IRS990ScheduleA/PublicSupportPY170Pct01
IRS990ScheduleA/PublicSupportTotal170Amt0947452
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt0123771
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt073805
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0260648
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt0410842
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt078386
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0947452
IRS990ScheduleA/TotalSupportAmt0947452
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Description;Amount^Charles River Laboratories Inc Wilmington MA 01887;51083|UTSW Viral Vector Core Dallas TX;37560|Greenwood Genetics Center;2000|National Organization for Rare Diseases;300|Travel Expences;1422|Bank Fees;563|Software and IT;177^Total;93105^
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Description;EOY Amount^Personal loan from J Taravella;20000^Total;20000^
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Form 990-EZ, Part I, Line 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Form 990-EZ, Part II, Line 26
ReasonableCauseExplanation/ExplanationTxt0Extension form was filed and accepted by IRS on May 15, 2025
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/PersonNm0Julia Taravella
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/PhoneNum05043883732
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-11-17
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0RARE TRAIT HOPE FUND
ReturnHeader/Filer/BusinessNameControlTxt0RARE
ReturnHeader/Filer/EIN0462762646
ReturnHeader/Filer/PhoneNum05044081126
ReturnHeader/Filer/USAddress/AddressLine1Txt0406 Schlief Drive
ReturnHeader/Filer/USAddress/CityNm0Belle Chasse
ReturnHeader/Filer/USAddress/StateAbbreviationCd0LA
ReturnHeader/Filer/USAddress/ZIPCd070037
ReturnHeader/IRSResponsiblePrtyInfoCurrInd01
ReturnHeader/ReturnTs02025-11-17T20:14:41-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-01-01
ReturnHeader/TaxPeriodEndDt02024-12-31
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2024 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$55,991
Liabilities
$20,000
Net assets
$35,991
Revenue
$103,771
Expenses
$93,647
Net income
$10,124
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$0.56$0.20$0.36$1.04$0.94$0.10
2023XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.26$0.00$0.26$0.74$2.22$1.48
2022Detailed filing. Detailed filing data is available for this year.$1.74$0.00$1.74$2.61$6.27$3.66
2021XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$5.41$0.00$5.41$4.11$0.73$3.37
2020Detailed filing. Detailed filing data is available for this year.$2.03$0.00$2.03$0.78$0.00$0.78
2019Summary only. Only limited summary data is available for this year.$1.25$0.00$0.32$0.08$0.24
2018Summary only. Only limited summary data is available for this year.$1.01$0.00$0.55$0.79$0.23
2017Summary only. Only limited summary data is available for this year.$1.24$0.00$0.70$0.03$0.66
2016Summary only. Only limited summary data is available for this year.$0.58$0.00$0.68$1.21$0.53
2015Summary only. Only limited summary data is available for this year.$1.11$0.00$1.04$0.76$0.28
2014Summary only. Only limited summary data is available for this year.$0.91$0.00$1.44$0.53$0.91